ZIM Laboratories Ltd

Net profit of Zim Laboratories declined 39.68% to Rs 4.88 crore in the quarter ended March 2025 as against Rs 8.09 crore during the previous quarter ended March 2024. Sales declined 7.75% to Rs 108.73 crore in the quarter ended March 2025 as against Rs 117.86 crore during the previous quarter ended March 2024. For the full year,net profit declined 29.45% to Rs 12.17 crore in the year ended March 2025 as against Rs 17.25 crore during the previous year ended March 2024. Sales rose 3.16% to Rs 379.03 crore in the year ended March 2025 as against Rs 367.42 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales108.73117.86 -8 379.03367.42 3 OPM %13.4313.28 -11.5411.25 - PBDT13.4014.90 -10 38.1239.59 -4 PBT8.1111.00 -26 18.0123.64 -24 NP4.888.09 -40 12.1717.25 -29 Powered by Capital Market - Live

Zim Laboratories will hold a meeting of the Board of Directors of the Company on 20 May 2025.Powered by Capital Market - Live

Zim Laboratories (ZIM) has entered into a Dossier License, Product Supply, and Technology Know-How License Agreement with Globalpharma Co. (L.L.C.), a leading UAE-based pharmaceutical manufacturer and a wholly owned subsidiary of Dubai Investments, one of the region's premier investment entities. This partnership encompasses dossier licensing, bulk product supply, and the licensing of ZIM Labs' proprietary Oral Thin Film technology platform, ThinOral'. Under the agreement, Globalpharma will register and commercialize 10 OTF-based Pharmaceutical and Nutraceutical products developed by ZIM, catering to regional patient needs with advanced, user-friendly dosage forms. Initially, ZIM Labs will supply bulk products while providing complete regulatory support for market registration in the UAE. Post-approval, ZIM will deliver ready-to-use powder mixes, enabling Globalpharma to undertake localized manufacturing and marketing of the finished formulations. Powered by Capital Market - Live

This authorization from INFARMED, which is the Portuguese National Authority of Medicines and Health Products, will facilitate faster approvals in other European Union countries as well as the UK and other markets globally resulting in better commercialisation opportunities, the company stated. Dimethyl Fumarate Modified Release Capsules are indicated for the treatment of relapsing forms of multiple sclerosis (MS) and are developed using ZIM's proprietary technology and is bioequivalent to the Innovator's product. According to IQVIA, the EU market size for this product in 2023 was approximately $800 million while UK contributed $200 million. Other markets (Ex USA & Japan) contributed $42 million. ZIM Laboratories Limited (the Company) is a research-driven Pharmaceutical company that develops, manufactures, and supplies differentiated generic products in oral solid dosage forms across key therapeutic segments. The company's consolidated net profit declined 16.32% to Rs 4 crore as revenue remained flat at Rs 96.33 crore in in the quarter ended December 2024 as compared with the previous quarter ended December 2023. The scrip rose 0.27% currently trade at to Rs 85 on the BSE. Powered by Capital Market - Live

Net profit of Zim Laboratories declined 16.32% to Rs 4.00 crore in the quarter ended December 2024 as against Rs 4.78 crore during the previous quarter ended December 2023. Sales rose 0.04% to Rs 96.33 crore in the quarter ended December 2024 as against Rs 96.29 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales96.3396.29 0 OPM %12.0111.98 - PBDT10.5810.95 -3 PBT5.707.01 -19 NP4.004.78 -16 Powered by Capital Market - Live

Zim Laboratories will hold a meeting of the Board of Directors of the Company on 10 February 2025.Powered by Capital Market - Live

ZIM Laboratories and Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders announced that Committee for Medicinal Products for Human Use (CHMP) has granted Marketing Authorization (MA) to Neuraxpharm, for Buprenorphine Sublingual Film in Europe, co -developed by ZIM LABS using its patented oral thin-film technology. Buprenorphine is indicated for the substitution treatment of opioid drug dependence. According to IQVIA, the European market for Buprenorphine-based opioid dependency treatments in 2023 surpassed USD 355 million annually, driven by increasing awareness and improved access to treatment programs. Further, the market size for Buprenorphine reached USD 1.3 billion in 2023. Developed using ZIM LABS' proprietary oral thin-film technology, the sublingual film offers rapid dissolution under the tongue for faster therapeutic action and improved patient compliance. This advanced formulation minimizes risks associated with misuse, respiratory depression, and overdose, setting a new benchmark in patient safety. Buprenorphine Sublingual Film follows the co-development agreement in Europe of novel oral thin films (OTF) between ZIM LABS and Neuraxpharm announced in 2019. Powered by Capital Market - Live

Zim Laboratories announced that the step-down Subsidiary has been incorporated in the name of 'ZIM SCIENTIFIC OFFICE L.L.C' in Dubai, United Arab Emirates. Powered by Capital Market - Live

Net profit of Zim Laboratories declined 42.65% to Rs 2.38 crore in the quarter ended September 2024 as against Rs 4.15 crore during the previous quarter ended September 2023. Sales rose 7.35% to Rs 92.14 crore in the quarter ended September 2024 as against Rs 85.83 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales92.1485.83 7 OPM %10.3410.87 - PBDT7.969.53 -16 PBT2.965.44 -46 NP2.384.15 -43 Powered by Capital Market - Live

Zim Laboratories will hold a meeting of the Board of Directors of the Company on 9 November 2024Powered by Capital Market - Live